Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $2,424,000.00 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Dianthus Therapeutics Trading Up 0.7%

Shares of Dianthus Therapeutics stock traded up $0.60 during trading on Thursday, hitting $82.49. 2,478,036 shares of the stock were exchanged, compared to its average volume of 927,592. The stock has a market capitalization of $4.51 billion, a price-to-earnings ratio of -19.97 and a beta of 1.18. The company has a fifty day moving average price of $86.81 and a 200-day moving average price of $66.00. Dianthus Therapeutics, Inc. has a 1-year low of $16.64 and a 1-year high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. First Horizon Corp bought a new position in Dianthus Therapeutics in the 1st quarter valued at about $32,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $40,000. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics during the second quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $64,000. Finally, ABS Direct Equity Fund LLC acquired a new position in shares of Dianthus Therapeutics in the first quarter valued at approximately $179,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on DNTH shares. Oppenheimer raised their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Wedbush lifted their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. HC Wainwright increased their price target on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $120.00 price target on Dianthus Therapeutics in a report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.